[Effect of 5'-DFUR used concurrently in radiotherapy and immunotherapy uterine cervical cancer--pilot study. Study of 5'-DFUR for Uterine Cervical Cancer].
We conducted a preliminary controlled study in order to evaluate 5'-DFUR dose dependency in efficacy and safety in combination therapy of radiotherapy, 5'-DFUR and SPG for patients with uterine cervical cancer, which was regarded as suitable for cases of radiotherapy. The patients were randomly allocated into group A (5'-DFUR 600 mg/body/day) and group B (5'-DFUR 800 mg/body/day), who underwent radiotherapy with simultaneous administration of 5'-DFUR and SPG (20 mg twice/week or 40 mg/ week). Those enrolled were 33 patients in stage II, III or IV a with histologically diagnosed primary squamous cell carcinoma of uterine cervix. CR was shown in 19, PR in 7, NC in 1, and PD in 2 out of 29 efficacy-evaluable cases, so the overall response rate was 89.7% (26/29, 95% CI 72.7%-97.8%). Regarding safety, some side effects were observed in 26 out of 33 safety-evaluable cases (81.3%, 95%, CI 63.6%-92.8%), but no serious cases. No significant difference in efficacy and safety was observed between the two treatment groups. These results suggested that the combination therapy of radiotherapy, 5'-DFUR and SPG might be one of the therapies whose effectiveness must be confirmed for advanced squamous cell carcinoma of uterine cervix. To confirm dose dependency of 5'-DFUR, it seems further consideration with more patients is needed.
Hatae
M
M
Dept. of Obstetrics and Gynecology, Kagoshima City Hospital.
Noda
K
K
Yajima
A
A
Sato
S
S
Terashima
Y
Y
Ochiai
K
K
Sasaki
H
H
Mizutani
K
K
Honjo
H
H
Yamamoto
T
T
Ozaki
M
M
Yamamoto
K
K
Hasegawa
K
K
Nishimura
R
R
Kudo
T
T
Kobashi
Y
Y
Yakushiji
M
M
Sugiyama
T
T
Hasuo
Y
Y
Onishi
Y
Y
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy / Q000628:therapy; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage*; D006801:Humans; D007167:Immunotherapy; D008875:Middle Aged; D010865:Pilot Projects; D012566:Sizofiran / Q000008:administration & dosage*; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy* / Q000628:therapy*
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D005467:Floxuridine; D012566:Sizofiran; C025034:doxifluridine